| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
181.65(B) |
| Last
Volume: |
2,611,876 |
Avg
Vol: |
2,730,756 |
| 52
Week Range: |
$214.27 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,117 |
4,213 |
23,771 |
32,103 |
| Total Sell Value |
$662,802 |
$1,235,078 |
$6,471,520 |
$8,588,219 |
| Total People Sold |
1 |
1 |
3 |
6 |
| Total Sell Transactions |
1 |
2 |
4 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sugar Ronald D |
Director |
• • – |
2021-01-13 |
4 |
AS |
$235.99 |
$235,990 |
D/D |
(1,000) |
15,805 |
|
2% |
|
| Sugar Ronald D |
Director |
• • – |
2021-01-13 |
4 |
OE |
$71.64 |
$71,640 |
D/D |
1,000 |
16,805 |
|
- |
|
| Williams R Sanders |
Director |
• • – |
2020-11-09 |
4 |
AS |
$242.40 |
$60,600 |
D/D |
(250) |
4,909 |
|
6% |
|
| Reese David M |
EVP, Research and Development |
• • – |
2020-11-02 |
4 |
D |
$216.94 |
$460,998 |
D/D |
(2,125) |
39,619 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2020-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,453 |
7,632 |
|
- |
|
| Gordon Murdo |
EVP Global Commercial Ops |
• • – |
2020-11-02 |
4 |
D |
$216.94 |
$1,359,997 |
D/D |
(6,269) |
32,036 |
|
- |
|
| Kullman Ellen Jamison |
Director |
• • – |
2020-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
141 |
6,846 |
|
- |
|
| Sugar Ronald D |
Director |
• • – |
2020-08-19 |
4 |
AS |
$241.02 |
$241,020 |
D/D |
(1,000) |
15,589 |
|
-4% |
|
| Sugar Ronald D |
Director |
• • – |
2020-08-19 |
4 |
OE |
$54.69 |
$54,690 |
D/D |
1,000 |
16,589 |
|
- |
|
| Williams R Sanders |
Director |
• • – |
2020-08-07 |
4 |
AS |
$242.95 |
$60,738 |
D/D |
(250) |
5,159 |
|
-5% |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2020-08-03 |
4 |
D |
$244.67 |
$70,954 |
D/D |
(290) |
11,026 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2020-08-01 |
4 |
D |
$244.67 |
$529,711 |
D/D |
(2,165) |
44,376 |
|
- |
|
| Miles Amy E |
Director |
• • – |
2020-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
408 |
408 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2020-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
8,174 |
11,316 |
|
- |
|
| Kullman Ellen Jamison |
Director |
• • – |
2020-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
241 |
6,663 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAOOfficer |
• – – |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,175 |
|
-10% |
|
| Sugar Ronald D |
Director |
• • – |
2020-07-22 |
4 |
AS |
$259.79 |
$259,790 |
D/D |
(1,000) |
15,589 |
|
-12% |
|
| Sugar Ronald D |
Director |
• • – |
2020-07-22 |
4 |
OE |
$54.69 |
$54,690 |
D/D |
1,000 |
16,589 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCOOfficer |
• – – |
2020-06-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
88 |
|
-1% |
|
| Grygiel Nancy A. |
SVP & CCOOfficer |
• – – |
2020-06-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,142 |
|
-1% |
|
| Sugar Ronald D |
Director |
• • – |
2020-06-17 |
4 |
AS |
$228.54 |
$228,540 |
D/D |
(1,000) |
15,576 |
|
-4% |
|
| Sugar Ronald D |
Director |
• • – |
2020-06-17 |
4 |
OE |
$54.69 |
$54,690 |
D/D |
1,000 |
16,576 |
|
- |
|
| Sugar Ronald D |
Director |
• • – |
2020-05-20 |
4 |
AS |
$229.27 |
$229,270 |
D/D |
(1,000) |
15,482 |
|
12% |
|
| Sugar Ronald D |
Director |
• • – |
2020-05-20 |
4 |
OE |
$54.69 |
$54,690 |
D/D |
1,000 |
16,482 |
|
- |
|
| Williams R Sanders |
Director |
• • – |
2020-05-06 |
4 |
AS |
$237.31 |
$100,857 |
D/D |
(425) |
5,409 |
|
7% |
|
2195 Records found
|
|
Page 15 of 88 |
|
|
2.71 (0.87%) 
